Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jiabin Jin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5007742703. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 1, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
67
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers, 2 trials · 2025: 3 papers · 2026: 2 papers

Papers 23

  1. Mechanisms of synergistic action between olaparib and KPT-330 in pancreatic cancer. Co-author DOI 10.1007/s10565-026-10219-7↗
  2. LLPS-based classification and a novel prognostic signature reveal NRF1 as a therapeutic target in pancreatic cancer. Co-author DOI 10.1186/s12935-026-04395-z↗
  3. Neobractatin and Trametinib Synergistically Induce Apoptosis and Gasdermin E-Dependent Pyroptosis in Pancreatic Cancer Cells. Co-author DOI 10.1002/mco2.70250↗
  4. A Mutual Interaction Between GSTP1 and p53 Improves the Drug Resistance and Malignant Biology of Pancreatic Cancer. Co-author DOI 10.1111/cas.70019↗
  5. Prevalence and clinical relavance of germline mutations in Chinese patients with pancreatic cancer. Last author DOI 10.1186/s12964-025-02281-1↗
  6. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  7. Cynanchum paniculatum (Bunge) Kitag. ex H.Hara inhibits pancreatic cancer progression by inducing caspase-dependent apoptosis and suppressing TGF-β-mediated ep… Co-author DOI 10.3389/fphar.2024.1284371↗
  8. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  9. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12967-023-04742-y↗
  10. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant … Co-author DOI 10.1002/cam4.4698↗
  11. Robotic versus open pancreaticoduodenectomy with vascular resection for pancreatic ductal adenocarcinoma: surgical and oncological outcomes from pilot experien… Co-author DOI 10.1007/s00423-021-02364-w↗
  12. Oncological outcomes of robotic pancreatectomy in patients with pancreatic cancer who receive adjuvant chemotherapy: A propensity score-matched retrospective c… Co-author DOI 10.1016/j.ijsu.2022.106801↗
  13. Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis. Co-author DOI 10.1007/s00464-020-07791-2↗
  14. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  15. LncRNA SNHG7 Regulates Mesenchymal Stem Cell Through the Notch1/Jagged1/Hes-1 Signaling Pathway and Influences Folfirinox Resistance in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.719855↗
  16. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  17. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. Co-author DOI 10.21037/jgo.2020.03.02↗
  18. Perineural invasion is related to p38 mitogen-activated protein kinase pathway activation and promotes tumor growth and chemoresistance in pancreatic cancer. Co-author DOI 10.1002/jcb.28457↗
  19. A new enhanced recovery after surgery pathway for left-sided pancreatic cancer patients after distal pancreatectomy. Co-author DOI 10.21037/tcr.2019.10.26↗
  20. Outcomes of robotic surgery for pancreatic ductal adenocarcinoma. Co-author DOI 10.3978/j.issn.1000-9604.2015.05.05↗
  21. A case-control study indicates that the TRIB1 gene is associated with pancreatic cancer. Co-author DOI 10.4238/2014.august.7.30↗
  22. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Co-author DOI 10.1007/s00441-013-1711-x↗
  23. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-013-0903-z↗

Trials 2

  1. In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor Principal investigator NCT06246630↗
  2. Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC Principal investigator NCT06573398↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaxing Deng · 12 shared papers, 2013–2023 · strength 1.38
  2. Baiyong Shen · 12 shared papers, 2013–2024 · strength 1.22
  3. Chenghong Peng · 13 shared papers, 2013–2023 · strength 1.19
  4. Kai Qin · 5 shared papers, 2021–2025 · strength 0.89
  5. Dongfeng Cheng · 7 shared papers, 2019–2023 · strength 0.79
  6. Baiyong Shen · 1 shared trial, 2024 · strength 0.68
  7. Yuanchi Weng · 5 shared papers, 2015–2022 · strength 0.61
  8. Baiyong Shen · 3 shared papers, 2022–2025 · strength 0.55
  9. Yu Jiang · 3 shared papers, 2021–2023 · strength 0.47
  10. Ningzhen Fu · 3 shared papers, 2021–2023 · strength 0.47
  11. Hao Chen · 6 shared papers, 2013–2021 · strength 0.42
  12. Haoda Chen · 2 shared papers, 2022–2026 · strength 0.42
  13. Xiongxiong Lu · 5 shared papers, 2013–2023 · strength 0.33
  14. Jun Zhang · 3 shared papers, 2020–2022 · strength 0.32
  15. Jiancheng Wang · 3 shared papers, 2020–2023 · strength 0.31
  16. Chenlei Wen · 3 shared papers, 2020–2023 · strength 0.31
  17. Yiran Zhou · 2 shared papers, 2021–2023 · strength 0.31
  18. Georgios Gemenetzis · 2 shared papers, 2022 · strength 0.31
  19. Qian Zhan · 5 shared papers, 2013–2021 · strength 0.30
  20. Hong‐Xi Xu · 1 shared paper, 2025 · strength 0.27
  21. Jiaqi Tan · 1 shared paper, 2025 · strength 0.27
  22. Xiaoming Wang · 1 shared paper, 2026 · strength 0.26
  23. Yuntao YANG · 1 shared paper, 2026 · strength 0.26
  24. Jiangning Gu · 3 shared papers, 2019–2020 · strength 0.26
  25. Hong Yu · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.